Author Archives: Marta Figueiredo PhD

Anavex 2-73 Slows Cognitive Decline in Alzheimer’s Patients, Phase 2 Extension Trial Shows

Treatment with Anavex‘s investigational therapy Anavex 2-73 significantly reduces cognitive decline in people with Alzheimer’s disease and sustains their ability to perform daily activities, according to interim data from a Phase 2 extension study. Trial results were presented in a late-breaking oral presentation, titled “Longitudinal 148-Week Extension Study…

CTD and Kerwin Center Discussing Partnership on Cholesterol-Lowering Therapies for Alzheimer’s

CTD Holdings and the Kerwin Research Center are discussing working together on the use of cholesterol-lowering therapies called cyclodextrins as possible treatments for Alzheimer’s disease. Cyclodextrins are non-toxic compounds made up of sugar molecules that can bind with and extract cholesterol. Preclinical-trial studies in Niemann-Pick disease and Alzheimer’s show they can…

Aduhelm Approved